mRNA Cancer Breakthrough Emerges Amid Trump's Vaccine Funding Cuts
Left says
- •The trial results show mRNA technology delivering real medical breakthroughs, undercutting political rhetoric that framed the platform as risky or unnecessary post-pandemic.
- •Cutting nearly $500 million in federal mRNA research funding threatens future innovations like this one, potentially slowing progress on treatments for other cancers.
- •Moderna's pivot from COVID vaccines to cancer therapy demonstrates the broader scientific value of mRNA research beyond the politically polarized vaccine debate.
- •The FDA's initial reluctance to review Moderna's flu vaccine reflects a troubling pattern of political interference in scientific and regulatory processes.
Right says
- •Skepticism toward mRNA technology stems from concerns raised during the pandemic about long-term safety data and rushed approval processes, not opposition to medical innovation itself.
- •Redirecting federal funding away from new vaccine development can reflect a broader philosophy of fiscal restraint and reassessing government spending priorities post-pandemic.
- •A private company's commercial success in developing a cancer treatment demonstrates that market incentives, not necessarily continued federal subsidy, can drive medical breakthroughs.
- •Distinguishing between mRNA vaccines for infectious disease and mRNA-based cancer therapies is reasonable, since concerns about the former don't automatically apply to the latter's distinct risk-benefit profile.
Common Take
High Consensus- The mRNA cancer treatment combining intismeran with Keytruda showed a clinically meaningful improvement over existing melanoma treatment in a large clinical trial.
- Moderna and Merck shares surged significantly following the announcement, reflecting strong market confidence in the results.
- The therapy showed no new safety risks compared to earlier studies of the treatment.
- Federal funding decisions for vaccine research have real consequences for the pace and direction of future medical innovation.
The Arguments
Left argues
The melanoma trial's success shows mRNA technology delivering concrete medical breakthroughs beyond COVID vaccines, proving the platform's value was never just a pandemic-era fluke and undercutting rhetoric that painted it as inherently risky.
Right counters
One promising trial result doesn't validate every use of mRNA technology or retroactively resolve legitimate concerns raised about the speed and transparency of the COVID vaccine rollout specifically.
Right argues
Distinguishing between mRNA vaccines for infectious disease and personalized mRNA cancer therapies is scientifically reasonable, since the two have very different risk-benefit calculations, patient populations, and regulatory pathways.
Left counters
That distinction is exactly why cutting funding indiscriminately across mRNA research is short-sighted—the same underlying platform technology enables both applications, so broad political cuts risk collateral damage to promising cancer therapies.
Right argues
Moderna and Merck's success was driven by private investment and market incentives, not continued federal subsidy, demonstrating that breakthrough medical innovation doesn't require open-ended government funding to succeed.
Left counters
Federal funding historically de-risks early-stage research that private companies won't touch alone; the mRNA platform itself was built substantially on decades of public investment before Moderna could commercialize it.
Left argues
The FDA's initial refusal to review Moderna's flu vaccine before reversing course suggests political considerations were influencing what should be a purely scientific regulatory process, which is a dangerous precedent regardless of one's views on mRNA.
Right counters
Regulatory caution or delay isn't automatically evidence of political interference—agencies routinely revisit initial decisions as more data or context becomes available, and reversing course can reflect due diligence rather than politicization.
Right argues
Skepticism about mRNA stems from genuine concerns about rushed timelines and incomplete long-term safety data during the pandemic, not a rejection of medical innovation or the technology itself.
Left counters
Years of real-world data and now a major cancer trial success suggest those safety concerns weren't borne out, yet the funding cuts remain framed in language that treats the entire platform as suspect rather than updating based on evidence.
Challenge Questions
These questions target genuine internal contradictions — meant to provoke honest reflection.
Right asks Left
“If mRNA's success in this cancer trial is presented as proof the technology was unfairly maligned, does that mean any past safety concerns about the COVID vaccines were entirely without merit, or is it possible both things can be true—effective cancer therapy and legitimate questions about the vaccine rollout?”
Left asks Right
“If the administration's stated rationale for cutting mRNA funding is fiscal restraint, why single out this specific platform rather than applying the same scrutiny evenly across other federally funded research areas, and does exempting cancer applications from that logic suggest the original safety framing was more political than scientific?”
Outlier Report
Left Fringe
Progressive health advocates and outlets like Media Matters commentators (~10-15% of the left) treat any mRNA skepticism as inherently anti-science, ignoring legitimate safety-data debates.
Right Fringe
RFK Jr., health freedom activists, and some MAHA-aligned voices (~15-20% of the right) reject mRNA technology broadly, even for cancer therapy, diverging from the more moderate right position distinguishing vaccine and therapeutic uses.
Noise Assessment
High on social media and cable news political framing; lower among general public, who mostly react positively to cancer treatment news independent of the funding cut controversy.
Sources (6)
<p>Moderna and Merck shares soared on Wednesday after the companies said a personalized <a href="https://www.axios.com/2024/05/07/how-mrna-vaccines-could-be-personalized-cancer-cures" target="_blank">mRNA treatment</a> hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. </p><p><strong>Why it matters:</strong> The results come at a pivotal moment for Moderna and mRNA research, after <a href="https://www.axios.com/politics-policy/donald-trump" target="_blank">Trump</a> administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards.</p><hr /><ul><li>The customized therapy, which could see a commercial launch next year, could also be adapted for other cancers of the kidney, bladder and pancreas.</li></ul><p><strong>The big picture: </strong>The results could lead to a remarkable turnaround for Moderna, whose market value plummeted more than 90% after demand for its <a href="https://www.axios.com/health/coronavirus" target="_blank">COVID</a> vaccine declined post-pandemic. The company this month also won <a href="https://feeds.issuerdirect.com/news-release.html?newsid=4801915282452025&symbol=MRNA" target="_blank">Food and Drug Administration approval</a> for a new mRNA seasonal flu vaccine.</p><ul><li>"People will experience this as ... the COVID company now [takes on] cancer," Moderna president Stephen Hoge told Axios. "But for those of us that live in it, it's like the cancer company that pivoted on a dime to help with COVID has pivoted back and really finally come home."</li></ul><p><strong>Driving the news: </strong>The experimental therapy, called intismeran, was tested in combination with Merck's cancer drug Keytruda in more than 1,100 patients with high-risk melanoma that had been surgically removed.</p><ul><li>The combination demonstrated a "clinically meaningful improvement" over treating the skin cancers with Keytruda alone.</li><li>The mRNA-based drugs essentially train the immune system to find mutations in a patient that cause tumors. That's a contrast to chemotherapy, which damages or destroys cancer cells.</li></ul><p><strong>"We may be entering an era</strong> where a patient's individual tumor biology can be used to design a therapy specifically for them," William Soliman, founder and CEO of the Accreditation Council for Medical Affairs, said in an email.</p><p><strong>The latest: </strong>The full results of the trial will be released at an upcoming medical meeting. </p><ul><li>But Wall Street has already responded enthusiastically, with shares of Moderna surging 177% Wednesday, while Merck shares closed up 12.6%.</li><li>"This is a landmark moment," TD Cowen analysts wrote in an investor note. "We view the result as a significant validation of the ... platform." </li></ul><p><strong>Between the lines:</strong> The safety profile of the combination treatment was consistent with earlier studies and showed no new risks.</p><ul><li>The findings showed early cancers might be treated more aggressively than with prior treatments that were more toxic to the body, Hoge said.</li></ul><p><strong>What we're watching:</strong> Whether the potential success of an mRNA-based cancer therapy could help lift the bigger cloud hanging over the technology. </p><ul><li>Political backlash following the pandemic — including the Trump administration pulling nearly $500 million in federal funding for mRNA research — raised questions about the field's long-term prospects.</li><li>The FDA initially refused to review Moderna's mRNA flu vaccine before changing course.</li><li>"I do hope that this will move people away from pigeonholing mRNA as a vaccine platform, or maybe even more incorrectly, tying it to the things they didn't like about the pandemic era that had nothing to do with the technology," Hoge said.</li><li>"I hope this starts to move us past that because it is, we think, a transformational moment in cancer." </li></ul><p><em>The story has been corrected to reflect that intismeran was jointly developed by Merck and Moderna (not just Moderna).</em></p>
The hostages are the second set to be released since the multiphase agreement came into effect, raising hopes for a lasting end to the war.
Israel says 91 hostages abducted on Oct. 7 remain in captivity, including the bodies of at least 34.
Aid workers estimate as many as 300,000 people are fleeing advances by the Rwandan-backed M23 rebel group, which has taken two strategic towns on the approaches to Goma over the past several days.
Israelis held their breath as four soldiers, all women, were released from the Gaza Strip, the second group to be freed as part of a fragile cease-fire agreement with Hamas.
The swap for four soldiers stationed on the border of the Gaza Strip at Nahal Oz follows 15 months of captivity and a campaign by their families.